PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
23272250-7	2012	Quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) shows that treatment with valproic acid (VPA) increases the recruitment of Kdm5a and Kdm6a to proximal promoter (PP) and proximal enhancer (PE) of Pou5f1 whereas enrichment of Ep300 and Kdm6b was seen in PP but not PE of Pou5f1 promoter.	Valproic Acid	85-98	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	245-250
22578249-4	2012	We also observed up-regulation of Jmjd3 gene expression in bEnd.3 endothelial cells that were subjected to oxygen-glucose deprivation/reperfusion injury.	oxygen-glucose	107-121	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	34-39
22578249-5	2012	When Jmjd3 was depleted by siRNA, oxygen-glucose deprivation/reperfusion injury-induced up-regulation of IL-6 was significantly inhibited.	oxygen-glucose	34-48	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	5-10
23251711-5	2012	The aim of this study was to evaluate the role of p63 during mouse neural stem cell (NSC) differentiation and test whether the histone H3 lysine 27-specific demethylase JMJD3 interacts with p63 to redirect NSCs to neurogenesis.	Lysine	138-144	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	169-174
23272250-7	2012	Quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) shows that treatment with valproic acid (VPA) increases the recruitment of Kdm5a and Kdm6a to proximal promoter (PP) and proximal enhancer (PE) of Pou5f1 whereas enrichment of Ep300 and Kdm6b was seen in PP but not PE of Pou5f1 promoter.	Valproic Acid	100-103	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	245-250
21483786-4	2011	In addition, the histone H3 lysine 27-specific demethylase JMJD3 induces ARF expression, thereby stabilizing p53 in mouse embryonic fibroblasts.	Lysine	28-34	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	59-64
18650421-9	2008	Microarray profiling revealed that, in TNF-alpha-stimulated monocytes, the induction of 25% NF-kappaB downstream genes, including the histone H3-lysine 27 demethylase JMJD3, was attenuated by SET7/9 depletion.	Lysine	145-151	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	167-172
19567879-3	2009	We report that M2-macrophage marker genes are epigenetically regulated by reciprocal changes in histone H3 lysine-4 (H3K4) and histone H3 lysine-27 (H3K27) methylation; and the latter methylation marks are removed by the H3K27 demethylase Jumonji domain containing 3 (Jmjd3).	Lysine	107-113	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	239-266
19567879-3	2009	We report that M2-macrophage marker genes are epigenetically regulated by reciprocal changes in histone H3 lysine-4 (H3K4) and histone H3 lysine-27 (H3K27) methylation; and the latter methylation marks are removed by the H3K27 demethylase Jumonji domain containing 3 (Jmjd3).	Lysine	107-113	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	268-273
20833714-4	2010	Cells from open caudal neural tubes of Sp(-/-) embryos exhibit increased H3K27 methylation and decreased expression of KDM6B possibly due to up-regulation of KDM6B targeting micro-RNAs such as miR-138, miR-148a, miR-185, and miR-339-5p.	TFF2 protein, human	39-41	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	119-124
20833714-4	2010	Cells from open caudal neural tubes of Sp(-/-) embryos exhibit increased H3K27 methylation and decreased expression of KDM6B possibly due to up-regulation of KDM6B targeting micro-RNAs such as miR-138, miR-148a, miR-185, and miR-339-5p.	TFF2 protein, human	39-41	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	158-163
20833714-10	2010	Thus, one of the mechanisms by which folate may rescue the Sp(-/-) phenotype is by increasing the expression of KDM6B, which in turn decreases H3K27 methylation marks on Hes1 and Neurog2 promoters thereby affecting gene transcription.	Folic Acid	37-43	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	112-117
20360974-4	2010	A Jumonji C family histone 3 lysine-27 (H3K27) demethylase, Jmjd3, plays a crucial role in macrophage plasticity and inflammation.	Lysine	29-35	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	60-65
34696686-5	2021	In the current study we identified, histone H3-lysine 27 trimethylation (H3K27me3)-specific demethylase, KDM6B to be upregulated in both cell culture and in murine model of Salmonella infection.	Lysine	47-53	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	105-110
18716661-0	2008	The histone H3 lysine 27-specific demethylase Jmjd3 is required for neural commitment.	Lysine	15-21	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	46-51
33033262-2	2020	Here, we demonstrate that the histone H3 lysine 27 trimethylation (H3K27me3) demethylase JMJD3 plays conflicting roles in mouse reprogramming.	Lysine	41-47	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	89-94
33033262-6	2020	This competition of forces can be shifted towards improved reprogramming by using early passage fibroblasts or boosting JMJD3"s catalytic activity with vitamin C.	Ascorbic Acid	152-161	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	120-125
34173271-5	2021	Here, we reported that conditional deletion of Jmjd3 in chondrogenic cells unexpectively resulted in BPOP-like lesion in mice.	bpop	101-105	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	47-52
34352276-7	2021	In addition, overexpression of JMJD3 weakened the protective effect of DexP on lung injury in mice with I/R.	dexp	71-75	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	31-36
34352276-8	2021	Collectively, the present results demonstrated that DexP ameliorates endothelial barrier dysfunction via the JMJD3/KGF-2 axis.	dexp	52-56	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	109-114
35191227-15	2022	Further analyses suggested that phosphoserine induced a M2-like phenotype in macrophages, which was related to the activation of phosphoserine receptors including T-cell immunoglobin mucin 4 (TIM4) and the FAK-SRC-STAT3 signaling pathway as well as elevated the expression of the histone demethylase Jumonji domain-containing protein 3 (JMJD3).	Phosphoserine	32-45	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	337-342
35278430-5	2022	Additionally, specific knockout of endothelial JMJD3 delayed EC regeneration, enhanced endothelial mesenchymal transition, impaired endothelial barrier function as determined by increased Evans blue staining and inflammatory cell infiltration, and accelerated neointima formation in the AVF created by venous end to arterial side anastomosis in CKD mice.	Evans Blue	188-198	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	47-52
35278430-8	2022	Furthermore, knockdown of endothelial JMJD3 decreased endothelial nitric oxide synthase expression and nitric oxide production, leading to the proliferation of vascular smooth muscle cells.	Nitric Oxide	103-115	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	38-43
33571671-8	2021	The H3K27me3 demethylase Jmjd3/UTX inhibitor GSKJ4 inhibited MEFs" differentiation into brown/beige adipocytes.	GSK-J4	45-50	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	25-30
34999729-8	2022	Both IL-15 and Kdm6b-mediated demethylation of histone 3 at lysine 27 are responsible for the maturation of TCRalphabeta+CD8alphaalpha+ IELs through upregulating the expression of Gzmb and Fasl.	Lysine	60-66	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	15-20
33556823-0	2021	Allyl sulfide promotes osteoblast differentiation and bone density via reducing mitochondrial DNA release mediated Kdm6b/H3K27me3 epigenetic mechanism.	allyl sulfide	0-13	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	115-120
33556823-8	2021	Mechanistically, AS or the mitochondrial-specific antioxidant Mito-TEMPO increased KDM6B expression and upregulated the expression of Runx2 in BMMSCs, probably via epigenetic inhibition of H3K27me3 methylation at the promoter.	MitoTEMPO	62-72	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	83-88
32405722-10	2021	It also questions to which extent KDM6B-mediated changes in H3K27me3 level account for the TET-mediated effects on gene expression.	tet	91-94	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	34-39
33349663-5	2021	We show, molecularly, that the interaction of the 6B strain with epithelial cells leads to chromatin remodelling within the IL-11 promoter in a KDM6B-dependent manner, where KDM6B specifically demethylates histone H3 lysine 27 dimethyl.	Lysine	217-223	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	144-149
33349663-5	2021	We show, molecularly, that the interaction of the 6B strain with epithelial cells leads to chromatin remodelling within the IL-11 promoter in a KDM6B-dependent manner, where KDM6B specifically demethylates histone H3 lysine 27 dimethyl.	Lysine	217-223	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	174-179
33981480-1	2021	Lysine demethylase 6B (KDM6B) is a histone H3 lysine 27 (H3K27) demethylase that serves as a key mediator of gene transcription.	Lysine	46-52	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	23-28
33414463-1	2021	Lysine (K)-specific demethylase 6B (KDM6B), a stress-inducible H3K27me3 demethylase, plays oncogenic or antitumoral roles in malignant tumors depending on the type of tumor cell.	Lysine	0-6	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	36-41
33456568-1	2021	Rationale: The Jumonji domain containing-3 (JMJD3), a specific histone demethylase for trimethylation on histone H3 lysine 27 (H3K27me3), is associated with the pathogenesis of many diseases, but its role in renal fibrosis remains unexplored.	Lysine	116-122	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	15-42
33340793-4	2021	The Jumonji domain protein 3 (JMJD3) is a specific histone demethylase of trimethylation at lysine 27 of histone-H3 (H3K27me3).	Lysine	92-98	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	4-28
33340793-4	2021	The Jumonji domain protein 3 (JMJD3) is a specific histone demethylase of trimethylation at lysine 27 of histone-H3 (H3K27me3).	Lysine	92-98	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	30-35
33456568-1	2021	Rationale: The Jumonji domain containing-3 (JMJD3), a specific histone demethylase for trimethylation on histone H3 lysine 27 (H3K27me3), is associated with the pathogenesis of many diseases, but its role in renal fibrosis remains unexplored.	Lysine	116-122	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	44-49
32662520-3	2020	Using monocyte-macrophages isolated from human blood and murine models, we demonstrate that palmitate (C16:0), the most abundant circulating SFA in T2D, increases expression of the histone demethylase, Jmjd3.	Palmitates	92-101	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	202-207
33391480-13	2021	The therapeutic effects of DZNep as epigenetic drug in liver fibrosis are associated with the regulation of EZH2 towards direct target genes encoding TGF-beta1 pseudoreceptor BAMBI, anti-inflammatory cytokine IL10 and cell cycle regulators CDKN1A, GADD45A and GADD45B, which are also regulated by JMJD3.	3-deazaneplanocin	27-32	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	297-302
33298158-8	2020	Chromatin immunoprecipitation and Western blot analyses found that GSK-J4 treatment elevated the levels of the Kdm6a and Kdm6b epigenetic target, the repressive mark of tri-methylated lysine 27 on histone 3, on osteogenic genes leading to repression of Runx2 and Alkaline Phosphatase expression.	Lysine	184-190	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	121-126
32662520-6	2020	Further, palmitate-induced Jmjd3 expression is controlled via TLR4/MyD88-dependent signaling mechanism, where genetic depletion of TLR4 (Tlr4-/- ) or MyD88 (MyD88-/- ) negated the palmitate-induced changes in Jmjd3 and downstream NFkappaB-induced inflammation.	Palmitates	9-18	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	27-32
32662520-6	2020	Further, palmitate-induced Jmjd3 expression is controlled via TLR4/MyD88-dependent signaling mechanism, where genetic depletion of TLR4 (Tlr4-/- ) or MyD88 (MyD88-/- ) negated the palmitate-induced changes in Jmjd3 and downstream NFkappaB-induced inflammation.	Palmitates	9-18	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	209-214
32662520-6	2020	Further, palmitate-induced Jmjd3 expression is controlled via TLR4/MyD88-dependent signaling mechanism, where genetic depletion of TLR4 (Tlr4-/- ) or MyD88 (MyD88-/- ) negated the palmitate-induced changes in Jmjd3 and downstream NFkappaB-induced inflammation.	Palmitates	180-189	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	27-32
32662520-8	2020	Together, we conclude that palmitate contributes to the chronic Jmjd3-mediated activation of macrophages in diabetic peripheral tissue and a histone demethylase inhibitor-based therapy may represent a novel treatment for nonhealing diabetic wounds.	Palmitates	27-36	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	64-69
31092054-2	2020	Jumonji domain-containing 3 (Jmjd3), also known as KDM6B, is a specific histone demethylase for trimethylation on histone H3 lysine 27 (H3K27me3) that specifically removes the methylation of H3K27me3 and promotes gene expression.	Lysine	125-131	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-27
31092054-2	2020	Jumonji domain-containing 3 (Jmjd3), also known as KDM6B, is a specific histone demethylase for trimethylation on histone H3 lysine 27 (H3K27me3) that specifically removes the methylation of H3K27me3 and promotes gene expression.	Lysine	125-131	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	29-34
31092054-2	2020	Jumonji domain-containing 3 (Jmjd3), also known as KDM6B, is a specific histone demethylase for trimethylation on histone H3 lysine 27 (H3K27me3) that specifically removes the methylation of H3K27me3 and promotes gene expression.	Lysine	125-131	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	51-56
32566254-5	2020	Inhibitors of Kdm6a and Kdm6b robustly abolished Zol-enhanced interleukin 1beta synthesis and secretion from macrophages.	Zoledronic Acid	49-52	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	24-29
32679234-6	2020	The interaction between miR-93-5p and lysine (K)-specific demethylase 6B (KDM6B) was identified using dual-luciferase reporter assay, and ChIP was used to validate the relationship between KDM6B and tumor necrosis factor-alpha (TNF-alpha).	mir-93-5p	24-33	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	74-79
32679234-6	2020	The interaction between miR-93-5p and lysine (K)-specific demethylase 6B (KDM6B) was identified using dual-luciferase reporter assay, and ChIP was used to validate the relationship between KDM6B and tumor necrosis factor-alpha (TNF-alpha).	mir-93-5p	24-33	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	189-194
32679234-6	2020	The interaction between miR-93-5p and lysine (K)-specific demethylase 6B (KDM6B) was identified using dual-luciferase reporter assay, and ChIP was used to validate the relationship between KDM6B and tumor necrosis factor-alpha (TNF-alpha).	Lysine	38-44	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	74-79
32566254-6	2020	When Kdm6a and Kdm6b were pharmacologically inhibited in vivo, poor healing of the alveolar socket and inflammatory responses were ameliorated in Zol-treated mice.	Zoledronic Acid	146-149	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	15-20
32566254-7	2020	Taken together, we showed the pathologic role of Kdm6a and Kdm6b in Zol-promoted inflammatory responses and demonstrated that Kdm6a and Kdm6b are potential therapeutic targets for the treatment of BRONJ.	Zoledronic Acid	68-71	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	59-64
32566254-7	2020	Taken together, we showed the pathologic role of Kdm6a and Kdm6b in Zol-promoted inflammatory responses and demonstrated that Kdm6a and Kdm6b are potential therapeutic targets for the treatment of BRONJ.	Zoledronic Acid	68-71	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	136-141
31971317-4	2020	Jmjd3 specific inhibitor GSK J4 or knocking down Jmjd3 significantly inhibited NLRP3 inflammasome activation in lipopolysaccharide (LPS) and nigericin-stimulated bone marrow-derived macrophages.	Nigericin	141-150	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-5
31971317-8	2020	Overall, our study reveals that Jmjd3 is a potential epigenetic regulator for the treatment of inflammatory bowel disease (IBD), suggesting that Nrf2 is a potential target gene of Jmjd3 by mediating methylation status of trimethylated H3 lysine 27 (H3K27me3) in the promotor and is required for NLRP3 inflammasome activation, thereby providing the platform for potential future therapeutic interventions in IBD.	tyrosyl-lysine	238-244	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	32-37
32223380-6	2020	Elevation of H3K27me3 levels was likely due to downregulation of the H3K27 (histone H3 Lys 27)-specific demethylase JMJD3 (the Jumonji domain containing-3) in the aged kidneys.	Lysine	87-90	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	116-121
32223380-6	2020	Elevation of H3K27me3 levels was likely due to downregulation of the H3K27 (histone H3 Lys 27)-specific demethylase JMJD3 (the Jumonji domain containing-3) in the aged kidneys.	Lysine	87-90	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	127-154
31971317-8	2020	Overall, our study reveals that Jmjd3 is a potential epigenetic regulator for the treatment of inflammatory bowel disease (IBD), suggesting that Nrf2 is a potential target gene of Jmjd3 by mediating methylation status of trimethylated H3 lysine 27 (H3K27me3) in the promotor and is required for NLRP3 inflammasome activation, thereby providing the platform for potential future therapeutic interventions in IBD.	tyrosyl-lysine	238-244	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	180-185
31971317-4	2020	Jmjd3 specific inhibitor GSK J4 or knocking down Jmjd3 significantly inhibited NLRP3 inflammasome activation in lipopolysaccharide (LPS) and nigericin-stimulated bone marrow-derived macrophages.	Nigericin	141-150	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	49-54
29254825-1	2018	The histone H3 lysine 27 (H3K27) demethylase Kdm6b (Jmjd3) can promote cellular differentiation, however its physiological functions in neurons remain to be fully determined.	Lysine	15-21	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	45-50
31102789-3	2019	Jmjd3 and Col1/3 expression was detected in a cystitis mouse model that was developed by intraperitoneal injection of cyclophosphamide (CYP).	Cyclophosphamide	118-134	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-5
31102789-3	2019	Jmjd3 and Col1/3 expression was detected in a cystitis mouse model that was developed by intraperitoneal injection of cyclophosphamide (CYP).	Cyclophosphamide	136-139	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-5
29074105-0	2018	Endogenous hydrogen sulfide regulates histone demethylase JMJD3-mediated inflammatory response in LPS-stimulated macrophages and in a mouse model of LPS-induced septic shock.	Hydrogen Sulfide	11-27	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	58-63
29074105-9	2018	This is the first report indicating that inflammation enhanced CSE/H2S system biosynthesis, that in turn attenuated the LPS-triggered inflammatory response by regulating JMJD3 expression.	Hydrogen Sulfide	67-70	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	170-175
31779639-0	2019	DHEA Attenuates Microglial Activation via Induction of JMJD3 in Experimental Subarachnoid Haemorrhage.	Dehydroepiandrosterone	0-4	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	55-60
31779639-8	2019	In cultured microglia, DHEA elevated the mRNA and protein levels of Jumonji d3 (JMJD3, histone 3 demethylase) after haemoglobin exposure, downregulated the H3K27me3 level, and inhibited the transcription of proinflammatory genes.	Dehydroepiandrosterone	23-27	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	68-78
31779639-8	2019	In cultured microglia, DHEA elevated the mRNA and protein levels of Jumonji d3 (JMJD3, histone 3 demethylase) after haemoglobin exposure, downregulated the H3K27me3 level, and inhibited the transcription of proinflammatory genes.	Dehydroepiandrosterone	23-27	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	80-85
31779639-9	2019	The devastating proinflammatory microglia-mediated effects on primary neurons were also attenuated by DHEA; however, specific inhibition of JMJD3 abolished the protective effects of DHEA.	Dehydroepiandrosterone	182-186	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	140-145
31779639-10	2019	We next verified that DHEA-induced JMJD3 expression, at least in part, through the tropomyosin-related kinase A (TrkA)/Akt signalling pathway.	Dehydroepiandrosterone	22-26	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	35-40
31779639-12	2019	Moreover, DHEA increases microglial JMJD3 expression to regulate proinflammatory/anti-inflammatory microglial activation after haemoglobin exposure, thereby suppressing inflammation.	Dehydroepiandrosterone	10-14	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	36-41
30375229-4	2018	To our knowledge, complex 1 is the first metal-based inhibitor of JMJD3 activity and only the second class of JMJD3 inhibitor reported overall.	Metals	41-46	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	66-71
29911994-0	2018	Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid beta-oxidation.	Fatty Acids	81-91	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	16-21
29911994-5	2018	Liver-specific downregulation of JMJD3 resulted in intrinsic defects in beta-oxidation, which contributed to hepatosteatosis as well as glucose and insulin intolerance.	Glucose	136-143	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	33-38
29911994-7	2018	JMJD3 histone demethylase may serve as an epigenetic drug target for obesity, hepatosteatosis, and type 2 diabetes that allows selective lowering of lipid levels without increasing glucose levels.	Glucose	181-188	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-5
29622035-12	2018	CONCLUSIONS: The GM-CSF Jmjd3 IRF4 CCL17 pathway is important for the development of CiOA, with CCL17 thus being a potential therapeutic target for the treatment of both OA pain and disease.	cioa	85-89	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	24-29
29254825-1	2018	The histone H3 lysine 27 (H3K27) demethylase Kdm6b (Jmjd3) can promote cellular differentiation, however its physiological functions in neurons remain to be fully determined.	Lysine	15-21	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	52-57
28323958-3	2017	In the present report, we generated genetically modified mice lacking histone H3 lysine 27 (H3K27) demethylase Jumonji domain-containing 3 (JMJD3) in hypothalamic rat-insulin-promoter-expressing neurons (RIP-Cre neurons).	HS 3	78-80	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	111-138
29070530-3	2018	Trimethylation of histone H3 on lysine 27 (H3K27me3) is regulated by Jumonji domain-containing protein 3 (JMJD3) and ubiquitously transcribed tetratricopeptide repeat on chromosome X (UTX) in a therapeutically targetable manner.	Lysine	32-38	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	69-104
29070530-3	2018	Trimethylation of histone H3 on lysine 27 (H3K27me3) is regulated by Jumonji domain-containing protein 3 (JMJD3) and ubiquitously transcribed tetratricopeptide repeat on chromosome X (UTX) in a therapeutically targetable manner.	Lysine	32-38	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	106-111
29070530-10	2018	Pharmacological inhibition of JMJD3 ameliorated bleomycin-induced and topoI-induced fibrosis in well-tolerated doses.	Bleomycin	48-57	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	30-35
28747667-2	2017	A novel synthetic histone 3 lysine 27 (H3K27) demethylase JMJD3 inhibitor, GSK-J4, was proven to exert immunosuppressive activities in macrophages.	Lysine	28-34	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	58-63
28323958-3	2017	In the present report, we generated genetically modified mice lacking histone H3 lysine 27 (H3K27) demethylase Jumonji domain-containing 3 (JMJD3) in hypothalamic rat-insulin-promoter-expressing neurons (RIP-Cre neurons).	HS 3	78-80	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	140-145
28323958-3	2017	In the present report, we generated genetically modified mice lacking histone H3 lysine 27 (H3K27) demethylase Jumonji domain-containing 3 (JMJD3) in hypothalamic rat-insulin-promoter-expressing neurons (RIP-Cre neurons).	Lysine	81-87	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	111-138
28323958-3	2017	In the present report, we generated genetically modified mice lacking histone H3 lysine 27 (H3K27) demethylase Jumonji domain-containing 3 (JMJD3) in hypothalamic rat-insulin-promoter-expressing neurons (RIP-Cre neurons).	Lysine	81-87	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	140-145
28188179-1	2017	Jmjd3 and Utx are demethylases specific for lysine 27 of histone H3.	Lysine	44-50	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-5
24703936-3	2014	Here we report that Jmjd3, a histone H3 lysine 27 (H3K27) demethylase, is highly inducible in SAA-stimulated macrophages and plays an important role in the induction of inflammatory cytokine genes.	Lysine	40-46	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	20-25
28423536-6	2017	Furthermore, we applied an agonist of the vitamin D receptor, paricalcitol, and found that it induced JMJD3 in breast cancer cells.	paricalcitol	62-74	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	102-107
28423536-9	2017	Administration of paricalcitol leads to upregulation of JMJD3 that suppresses Oct4 expression and the stem cell-like characteristics in breast cancer.	paricalcitol	18-30	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	56-61
27528513-1	2016	As it has been established that demethylation of lysine 27 of histone H3 by the lysine-specific demethylase JMJD3 increases immune responses and thus elicits inflammation, we hypothesize that inhibition of JMJD3 may attenuate autoimmune disorders.	Lysine	49-55	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	108-113
27528513-1	2016	As it has been established that demethylation of lysine 27 of histone H3 by the lysine-specific demethylase JMJD3 increases immune responses and thus elicits inflammation, we hypothesize that inhibition of JMJD3 may attenuate autoimmune disorders.	Lysine	49-55	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	206-211
27528513-1	2016	As it has been established that demethylation of lysine 27 of histone H3 by the lysine-specific demethylase JMJD3 increases immune responses and thus elicits inflammation, we hypothesize that inhibition of JMJD3 may attenuate autoimmune disorders.	Lysine	80-86	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	108-113
27528513-1	2016	As it has been established that demethylation of lysine 27 of histone H3 by the lysine-specific demethylase JMJD3 increases immune responses and thus elicits inflammation, we hypothesize that inhibition of JMJD3 may attenuate autoimmune disorders.	Lysine	80-86	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	206-211
26655900-4	2015	We demonstrate that BAF complexes interact with H3K27 demethylases (JMJD3 and UTX) and potentiate their activity.	triazinate	20-23	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	68-73
26776360-0	2016	Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.	pyrimidine	28-38	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	94-99
26776360-0	2016	Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.	Nitrogen	47-55	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	94-99
25840993-3	2015	We demonstrated here that histone H3 lysine-27 (H3K27) demethylation, predominantly mediated by the H3K27 demethylase Jmjd3, crucially regulated Th17 cell differentiation.	Lysine	37-43	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	118-123
25652097-8	2015	Moreover, we report that the interplay between SUZ12 and JMJD3 results in dynamic regulation of lysine 27 trimethylation of histone 3 (H3K27me3).	Lysine	96-102	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	57-62
25535150-0	2015	Vitamin C facilitates dopamine neuron differentiation in fetal midbrain through TET1- and JMJD3-dependent epigenetic control manner.	Ascorbic Acid	0-9	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	90-95
25535150-0	2015	Vitamin C facilitates dopamine neuron differentiation in fetal midbrain through TET1- and JMJD3-dependent epigenetic control manner.	Dopamine	22-30	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	90-95
25535150-4	2015	VC induced gain of 5-hydroxymethylcytosine (5hmC) and loss of H3K27m3 in DA phenotype gene promoters, which are catalyzed by Tet1 and Jmjd3, respectively.	Ascorbic Acid	0-2	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	134-139
25535150-4	2015	VC induced gain of 5-hydroxymethylcytosine (5hmC) and loss of H3K27m3 in DA phenotype gene promoters, which are catalyzed by Tet1 and Jmjd3, respectively.	5-hydroxymethylcytosine	19-42	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	134-139
25535150-4	2015	VC induced gain of 5-hydroxymethylcytosine (5hmC) and loss of H3K27m3 in DA phenotype gene promoters, which are catalyzed by Tet1 and Jmjd3, respectively.	5-hydroxymethylcytosine	44-48	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	134-139
24983519-3	2014	Pilocarpine drove a 20-fold increase in mRNA encoding the histone H3 lysine 27-specific demethylase Kdm6b selectively in granule neurons of the dentate gyrus, and this induction was recapitulated in cultured hippocampal neurons by bicuculline and 4-aminopyridine (Bic + 4AP) stimulation of synaptic activity.	Pilocarpine	0-11	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	100-105
24983519-3	2014	Pilocarpine drove a 20-fold increase in mRNA encoding the histone H3 lysine 27-specific demethylase Kdm6b selectively in granule neurons of the dentate gyrus, and this induction was recapitulated in cultured hippocampal neurons by bicuculline and 4-aminopyridine (Bic + 4AP) stimulation of synaptic activity.	Lysine	69-75	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	100-105
24983519-3	2014	Pilocarpine drove a 20-fold increase in mRNA encoding the histone H3 lysine 27-specific demethylase Kdm6b selectively in granule neurons of the dentate gyrus, and this induction was recapitulated in cultured hippocampal neurons by bicuculline and 4-aminopyridine (Bic + 4AP) stimulation of synaptic activity.	Bicuculline	231-242	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	100-105
24983519-3	2014	Pilocarpine drove a 20-fold increase in mRNA encoding the histone H3 lysine 27-specific demethylase Kdm6b selectively in granule neurons of the dentate gyrus, and this induction was recapitulated in cultured hippocampal neurons by bicuculline and 4-aminopyridine (Bic + 4AP) stimulation of synaptic activity.	4-Aminopyridine	247-262	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	100-105
24983519-3	2014	Pilocarpine drove a 20-fold increase in mRNA encoding the histone H3 lysine 27-specific demethylase Kdm6b selectively in granule neurons of the dentate gyrus, and this induction was recapitulated in cultured hippocampal neurons by bicuculline and 4-aminopyridine (Bic + 4AP) stimulation of synaptic activity.	bic + 4ap	264-273	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	100-105
24983519-5	2014	Prior exposure to Bic + 4AP promoted neuronal survival in control neurons upon growth factor withdrawal; however, this effect was ablated when we knocked down Kdm6b expression.	bic + 4ap	18-27	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	159-164
24646476-1	2014	Jmjd3 is required for cellular differentiation and senescence, and inhibits the induction of pluripotent stem cells by demethylating histone 3 lysine 27 trimethylation (H3K27me3).	Lysine	143-149	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-5
24646476-8	2014	Jmjd3 is localized both into the cytoplasm and the nucleus, and its nuclear export is dependent on Exportin-1, as treatment with leptomycin B triggers nuclear accumulation of Jmjd3.	leptomycin B	129-141	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	0-5
24646476-8	2014	Jmjd3 is localized both into the cytoplasm and the nucleus, and its nuclear export is dependent on Exportin-1, as treatment with leptomycin B triggers nuclear accumulation of Jmjd3.	leptomycin B	129-141	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	175-180
23772023-3	2013	In this report, we define a STAT4-dependent sequence of events including histone H3 lysine 4 methylation, Jmjd3 association with STAT4 target loci, and a Jmjd3-dependent decrease in histone H3 lysine 27 trimethylation and DNA methyltransferase (Dnmt) 3a association with STAT4 target loci.	Lysine	193-199	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	154-159
24212761-6	2014	We also observed that the suppression of Jmjd3 in the substantia nigra (SN) in vivo dramatically caused microglial overactivation and exacerbated dopamine (DA) neuron death in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-intoxicated mouse model of PD.	Dopamine	146-154	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	41-46
24212761-6	2014	We also observed that the suppression of Jmjd3 in the substantia nigra (SN) in vivo dramatically caused microglial overactivation and exacerbated dopamine (DA) neuron death in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-intoxicated mouse model of PD.	Dopamine	156-158	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	41-46
24212761-6	2014	We also observed that the suppression of Jmjd3 in the substantia nigra (SN) in vivo dramatically caused microglial overactivation and exacerbated dopamine (DA) neuron death in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-intoxicated mouse model of PD.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	176-223	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	41-46
24212761-6	2014	We also observed that the suppression of Jmjd3 in the substantia nigra (SN) in vivo dramatically caused microglial overactivation and exacerbated dopamine (DA) neuron death in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-intoxicated mouse model of PD.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	225-229	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	41-46
23103168-4	2012	Here, we inactivated Jmjd3 in the mouse and found that its loss causes perinatal lethality with the complete and selective disruption of the pre-Botzinger complex (PBC), the pacemaker of the respiratory rhythm generator.	potassium bicarbonate	164-167	KDM1 lysine (K)-specific demethylase 6B	Mus musculus	21-26